03 — Health Care Cost & Coverage

03 — Health Care Cost & Coverage

Stage 1: EVIDENCE BRIEF

Referee panel: Prof. Olivia Brandt (#57, statistics, C) · Prof. June Takahashi (#17, econometrics, C) · domain specialist Prof. Hannah Okafor (#9, health economics, C)

Ground rules from the panel: every number below is recorded as the source states it, with the data year. Where two reputable sources give different numbers for "the same" thing, we say so rather than choosing the one we like. Two items we tried to verify and could not (an Urban Institute single-payer score page returned 404; a precise count of drugs "lost" from a University of Chicago paper) are flagged as unverified and not used as facts.

---

A. How much, and compared to whom

1. U.S. national health expenditure (NHE) was $5.3 trillion in 2024, up 7.2%, equal to 18.0% of GDP (up from 17.7% in 2023). CMS Office of the Actuary, NHE 2024 Highlights (data year 2024). https://www.cms.gov/files/document/highlights.pdf
2. Per-capita NHE was $15,474 in 2024. CMS actuaries' annual article, Health Affairs (2025/26), data year 2024. https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.01683
3. Composition 2024: hospital care $1.6T (31%, +8.9%); physician & clinical $1.1T (21%, +8.1%); retail Rx $467.0B (9%, +7.9%). Payers: private insurance $1.6T (31%), Medicare $1.1T (21%), Medicaid $931.7B (18%), out-of-pocket $556.6B (11%). CMS Highlights (2024).
4. International comparison (OECD definition, "health consumption expenditure"): U.S. $14,775 per person in 2024 vs. a comparable-country average of $7,860; the U.S. spent ~$5,000 more per person than the next-highest peer, Switzerland. Share of GDP on this narrower definition: U.S. 17.2% vs. 11.2% peer average (2024). Peterson-KFF Health System Tracker. https://www.healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/

• Referee note (Brandt): 18.0% (NHE) and 17.2% (OECD consumption concept) are both correct; they measure different things (NHE includes investment/research). Anyone quoting one against the other is comparing apples to applesauce.

1. Where the gap sits (2021 data): U.S. $12,197 vs. peers' $6,514 per capita — a $5,683 gap. Inpatient + outpatient care account for $4,531 (~80%); administration ~$680 (~12%); drugs & medical goods ~$691 (~12%). Administration = 7.6% of U.S. spending vs. 3.8% in peers. Peterson-KFF. https://www.healthsystemtracker.org/brief/what-drives-health-spending-in-the-u-s-compared-to-other-countries/
2. Swiss and Dutch "managed competition" systems: Switzerland — mandatory basic insurance bought from private nonprofit insurers, community-rated by insurer/canton, income-based premium subsidies, risk adjustment, CHF 300 deductible + 10% coinsurance; 11.7% of GDP (2023), out-of-pocket 22% of spending. https://www.commonwealthfund.org/international-health-policy-center/countries/switzerland · Netherlands — mandatory statutory insurance from private nonprofit insurers, guaranteed issue, central risk equalization, EUR 385 compulsory deductible (2025; coalition proposes EUR 165 from 2027); 10.1% of GDP (2022). https://www.commonwealthfund.org/international-health-policy-center/countries/netherlands
3. **Commonwealth Fund Mirror, Mirror 2024: U.S. ranks last overall of 10 countries; but 2nd on "care process"** (prevention, safety). Australia, Netherlands, UK top three. https://www.commonwealthfund.org/publications/fund-reports/2024/sep/mirror-mirror-2024

B. Prices vs. utilization

1. Papanicolas, Woskie & Jha (JAMA 2018, 2016 data): U.S. spent 17.8% of GDP vs. 9.6–12.4% in 10 peers; utilization broadly similar; administrative costs 8% vs. 1–3%; pharmaceuticals $1,443 per capita vs. a $749 peer mean; GP salaries $218,173 vs. $86,607–$154,126. Authors: "reform efforts aimed at utilization alone are unlikely to have an impact on spending." https://jamanetwork.com/journals/jama/fullarticle/2674671 (summary: https://www.ajmc.com/view/healthcare-spending-driven-by-price-not-utilization-ijamai-study-)
2. Anderson, Hussey & Petrosyan, "It's Still the Prices, Stupid" (Health Affairs, Jan 2019): U.S. provides fewer real resources than the OECD median (beds, physicians, nurses), so higher spending must reflect higher prices; gap between public and private payment rates widened over 15 years. https://www.healthaffairs.org/doi/10.1377/hlthaff.2018.05144 (RAND abstract: https://www.rand.org/pubs/external_publications/EP67983.html)
3. **But — 2024 spending growth was mostly volume, not price. CMS actuaries: non-price factors (use and intensity) contributed 3.6 percentage points to per-capita growth vs. 2.5 points** for medical prices. https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.01683
4. Within the U.S., privately insured spending per beneficiary varies ~3x across areas, driven equally by price and quantity. Cooper, Craig, Gaynor & Van Reenen, QJE 2019 / NBER w21815 (claims covering 28% of ESI market, 2007–2011). https://www.nber.org/papers/w21815

C. Hospital consolidation and commercial prices

1. Monopoly hospitals' prices are 12% higher than in markets with 4+ rivals; mergers of hospitals ≤5 miles apart raised prices by over 6% (366 mergers, 2007–2011); concentrated insurer markets have lower hospital prices. Cooper et al. https://www.nber.org/papers/w21815
2. Private plans paid hospitals 254% of Medicare rates in 2022 (inpatient 255%, outpatient facility 289%, professional 188%, ASCs 170%); >4,000 hospitals, 49 states + DC. RAND Round 5.1. https://www.rand.org/news/press/2024/05/13.html
3. CBO (2022): commercial prices for hospital and physician services are much higher than Medicare FFS and rising faster; provider market power is the leading explanation; and "the share of providers' patients who are covered by Medicare and Medicaid is not related to higher prices paid by commercial insurers" — i.e., CBO finds little support for the cost-shifting hypothesis. https://www.cbo.gov/publication/57422

D. Site-neutral payment and transparency

1. CBO scores of site-neutral options (via KFF): drug administration in off-campus HOPDs (Lower Costs, More Transparency Act) ~$4B/10 yrs; all off-campus HOPD services ~$39B/10 yrs; on-campus HOPD services commonly provided in non-hospital settings ~$102B/10 yrs. MedPAC: its recommended alignment would cut OPPS hospitals' Medicare revenue ~3.8% and beneficiary cost-sharing ~$1.5B (2021). https://www.kff.org/medicare/five-things-to-know-about-medicare-site-neutral-payment-reforms/
2. Hospital price transparency rule (effective Jan 1, 2021): PatientRightsAdvocate.org's eighth semi-annual review of 2,000 hospitals found 49.4% fully compliant — the highest yet, up from 21% in its prior review; many still post algorithms/percentages instead of dollar prices. (Advocacy group; methodology stricter than CMS's.) https://www.patientrightsadvocate.org/
3. Consumers under deductibles do not price-shop: after a firm moved employees from free care to an HDHP, spending fell 11.79–13.80%, entirely from reduced quantity; "no evidence of consumers learning to price shop after two years"; reductions hit both imaging and preventive care. Brot-Goldberg, Chandra, Handel & Kolstad, NBER w21632 (QJE 2017). https://www.nber.org/papers/w21632

E. Cost-sharing and coverage experiments

1. RAND Health Insurance Experiment (1971–82): 25% coinsurance → 20% less spending vs. free care; ~30% less at higher coinsurance; no adverse health effects on average, except for the poorest and sickest ~6% (hypertension control, vision, etc.); cost sharing cut effective and less-effective care alike. https://www.rand.org/pubs/research_briefs/RB9174.html
2. Oregon Health Insurance Experiment (2008 lottery): Medicaid raised outpatient visits, hospitalizations, prescriptions and ED use; virtually eliminated catastrophic out-of-pocket expenditures; substantially reduced depression; no statistically significant effect on blood pressure, cholesterol, or cardiovascular risk over ~2 years; no significant employment effect. https://www.nber.org/programs-projects/projects-and-centers/oregon-health-insurance-experiment

F. Coverage now and after the 2025 law

1. Census CPS ASEC 2025: 26.7 million (7.9%) uninsured for all of 2025, not statistically different from 2024; Medicaid coverage −0.5 pts. https://www.census.gov/newsroom/press-releases/2026/income-poverty-health-insurance-coverage.html
2. NCHS NHIS 2025: 8.3% uninsured (28.0 million) at interview; adults 18–64 11.6%; non-expansion states 18.1% vs. expansion states 9.0%; children 5.6% (up from 5.1%). https://www.cdc.gov/nchs/pressroom/releases/20260528.html
3. CBO on the enacted One Big Beautiful Bill Act (P.L. 119-21), July 2025: +10 million uninsured in 2034; ~$1.06 trillion less federal spending on Medicaid and marketplaces over 2025–2034 (work/community-engagement requirements ~$325.6B; provider-tax freeze ~$191.1B; state-directed payments ~$149.4B); deficit +$3.4T overall. https://www.aha.org/news/headline/2025-07-21-cbo-projects-obbba-increase-uninsured-10-million-federal-deficit-34-trillion
4. CBO (June 2025, House-passed version) decomposition, via KFF: 7.8M from Medicaid provisions + 3.1M marketplace provisions + 0.9M from codifying the marketplace integrity rule + 4.2M from expiration of the enhanced premium tax credits = ~16M more uninsured in 2034. (Final-law Medicaid number differs slightly; the 4.2M eAPTC figure is separate from the bill.) https://www.kff.org/medicaid/how-will-the-2025-budget-reconciliation-affect-the-aca-medicaid-and-the-uninsured-rate/ ; CBO letter: https://www.cbo.gov/publication/61463
5. Enhanced PTCs expired Dec 31, 2025. House passed a 3-year extension (H.R. 1834) 230–196 on Jan 8, 2026; Senate did not reach 60 votes on alternatives; no extension enacted as of the ASTHO tracker. https://www.astho.org/communications/blog/2026/aca-enhanced-premium-tax-credits-legislative-developments-2025-2026/
6. Marketplace enrollment 2026: 22.1M (2025) → 19.2M (Feb 2026), −2.9M (−13%); average net premium payments +58% (+114% to keep the same plan); deductibles +37%; KFF projects average ~17.5M for 2026. https://www.kff.org/quick-insights/aca-marketplace-enrollment-is-down-by-3-million-after-big-jump-in-premium-payments/

G. Drugs

1. IRA negotiation, round 1 (10 Part D drugs, prices effective Jan 2026): would have saved ~$6B (22% net) had prices applied in 2023; ~$1.5B beneficiary OOP savings. Round 2 (15 drugs incl. semaglutide, effective 2027): ~$12B savings, ~44%; semaglutide set at $274/30 days vs. $959 list. Round 3 (15 Part B + D drugs, 2028) selected Jan 2026. All 40 drugs = 36% of 2024 Part B+D spending. https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/ ; https://www.biopharmadive.com/news/medicare-price-negotiation-wegovy-ozempic-trelegy-2027/806526/

• Referee note (Takahashi): KFF describes the round-2 44% as relative to net prices; some trade press describes it relative to list. We treat "vs. net" as the CMS basis; anyone who says "44% off list" is being imprecise.

1. CBO on innovation: IRA drug provisions → ~13 fewer new drugs out of ~1,300 over 30 years (~1%); negotiation saves Medicare ~$98.5B over 2022–2031 (original score). https://www.kff.org/medicare/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
2. Industry-side estimates are much larger — e.g., Philipson and coauthors (U. Chicago) on the 9-vs-13-year "pill penalty" for small molecules. https://bpb-us-w2.wpmucdn.com/voices.uchicago.edu/dist/d/3128/files/2023/10/Small-Molecule-Paper-Final-Oct-5-2023.pdf — the panel could not independently verify a single headline count from this paper; treat any specific number attributed to it in this thread as unverified.

H. Outcomes

1. U.S. life expectancy 2024: 79.0 years (+0.6), age-adjusted death rate −3.8%. NCHS Data Brief 548. https://www.cdc.gov/nchs/products/databriefs/db548.htm
2. Peer gap: 79.0 vs. 82.7 comparable-country average (2024), a 3.7-year gap. Drivers cited: overdoses/unintentional injuries, chronic disease (diabetes, kidney, liver), inequality, access. https://www.healthsystemtracker.org/chart-collection/u-s-life-expectancy-compare-countries/
3. Cause profile: U.S. cancer mortality is among the lowest of peers; U.S. is worse on circulatory, respiratory, metabolic, and external causes; maternal mortality >4x peers. https://www.healthsystemtracker.org/chart-collection/mortality-rates-u-s-compare-countries/
4. Overdoses fell sharply: 79,384 deaths in 2024; age-adjusted rate 31.3 → 23.1 per 100k (−26.2%), synthetic opioids −35.6%. NCHS Data Brief 549. https://www.cdc.gov/nchs/products/databriefs/db549.htm
5. "Missing Americans": ~622,534 excess U.S. deaths vs. peer mortality in 2019 and ~1.09M in 2021; 49% were under age 65. Bor et al., PNAS Nexus 2023. https://academic.oup.com/pnasnexus/article/2/6/pgad173/7187950

I. Administration, reform scores, workforce, debt

1. Himmelstein, Campbell & Woolhandler (Annals 2020, 2017 data): U.S. administrative costs $812B, 34.2% of NHE ($2,497 per capita) vs. Canada 17.0% ($551). https://www.acpjournals.org/doi/10.7326/M19-2818

• Referee note (Brandt): 34.2% uses a broad definition (incl. provider billing time); the OECD/Peterson figure (item 5) of 7.6% counts only insurer/government administration. Both are real; neither is "the" admin cost.

1. CBO single-payer options (Dec 2020 working paper): federal subsidies +$1.5T to +$3.0T in 2030; national health spending between −$0.7T and +$0.3T depending on design; nearly universal coverage; demand would outpace supply → more unmet demand/waits, especially under low payment rates + low cost sharing. https://www.cbo.gov/publication/56811
2. Mercatus (Blahous 2018) on M4A (S.1804): +$32.6T federal commitments 2022–2031; assumes provider payments >40% below private rates. https://www.mercatus.org/research/working-papers/costs-national-single-payer-healthcare-system
3. CBO on a public option (2021): premiums "could be higher or lower" than private plans depending mostly on provider payment rates; budget effect hinges on that. https://www.cbo.gov/publication/57020
4. Physician supply: AAMC projects a shortage of up to 86,000 physicians by 2036. https://www.aamc.org/news/press-releases/new-aamc-report-shows-continuing-projected-physician-shortage
5. Medical debt: ≥$220B owed; ~14M adults (6%) owe >$1,000, ~3M (1%) >$10,000 (SIPP 2021; KFF Feb 2024). https://www.kff.org/health-costs/issue-brief/the-burden-of-medical-debt-in-the-united-states/

---

CONTESTED EVIDENCE (where the literature genuinely disagrees)

C1. Prices or quantities? Papanicolas (2018) and Anderson (2019) say prices explain the level gap. But CMS attributes most of 2024's per-capita growth to use/intensity (3.6 vs 2.5 pts), and Cooper et al. find within-U.S. variation is half quantity. A further camp (not cited as fact here — we could not fetch a primary source within budget) argues U.S. spending tracks its unusually high household consumption per capita. Panel view: "It's the prices" is well supported for the level of U.S.–OECD spending on hospital/physician care; it is not a complete account of growth or of within-U.S. variation.

C2. How big is administrative waste, and how much is recoverable? 34.2% (Himmelstein et al., broad) vs. 7.6% (OECD, narrow). CBO's single-payer range — spending anywhere from −$0.7T to +$0.3T — shows the answer depends on payment rates and cost sharing, not on admin savings alone.

C3. Does coverage improve physical health? Oregon: large financial and mental-health gains, no significant 2-year change in BP/cholesterol/HbA1c-risk. Quasi-experimental Medicaid-expansion mortality studies (not fetched here) find mortality reductions; the RCT was underpowered for mortality. Genuinely contested.

C4. Does cost-sharing discipline prices? RAND HIE: cost sharing reduces use without average harm (except poor/sick). Brot-Goldberg: no price shopping, cuts to valuable care. Consumer-driven advocates argue HSA+transparency ecosystems are newer than these studies. Contested on prices; well-established on quantities.

C5. Innovation cost of drug price negotiation. CBO ~1% fewer drugs over 30 years vs. much larger industry-affiliated estimates. Different elasticities of R&D to expected revenue drive the gap; neither side has post-2026 outcome data yet.

C6. Transparency rule effects. Compliance has improved (21% → 49.4% on PRA's strict test), but we found no strong causal evidence yet that posted prices have lowered negotiated rates; theory cuts both ways (transparency can also facilitate tacit coordination).

C7. Coverage losses from 2025–26 changes. CBO projects +10M uninsured by 2034 from the law plus ~4.2M from eAPTC expiration; realized 2025 uninsured was flat (Census 7.9%) because most Medicaid provisions (work requirements from end-2026) had not yet started. Early 2026 marketplace data (−2.9M) are enrollment, not uninsurance.

— Brandt, Takahashi, Okafor

Stage 2: OPENING POSITIONS — Part 1 (Left bloc)

---

Prof. Diane Mercer (#41, public health · L)

Causal claim. The United States does not have a utilization problem; it has a price problem and a coverage problem, and the two compound. We pay roughly double the peer average per person ($14,775 vs. $7,860 in 2024, Brief #4) for a population that is not using more care (Papanicolas 2018, Brief #8; Anderson 2019, Brief #9). Prices explain essentially all of the gap. Meanwhile, the life-expectancy gap — 3.7 years (Brief #30) — is fundamentally the product of our lack of universal coverage.

Evidence. Papanicolas: similar utilization, far higher prices for drugs, procedures, salaries. RAND: private plans pay 254% of Medicare (Brief #13). The Bor et al. "missing Americans" count — 1.09 million excess deaths in 2021, half under 65 (Brief #33) — is what an uninsured, under-insured country looks like.

Remedy. Universal coverage financed publicly, with all-payer rate setting anchored to Medicare-plus.

Tradeoff I concede. Rate-setting will cut hospital revenue, and some rural hospitals already on thin margins will need explicit global budgets or they will close.

Falsifiable prediction. If the coverage losses CBO projects (+10M from the law, +4.2M from eAPTC expiration; Brief #22–23) materialize, age-adjusted mortality among 50–64-year-olds in non-expansion and work-requirement states will diverge (worsen relative to other states) within 4 years of 2027.

---

Prof. Rosa Delgado-Finch (#7, political economy · Soc)

Causal claim. The multi-payer system is itself the cost driver. It generates an administrative apparatus consuming a third of all health spending — 34.2%, $812B in 2017 (Himmelstein et al., Brief #34) — versus 17% in Canada. It also fragments purchasing power so that hospitals with market power can extract monopoly rents from each small insurer.

Evidence. Himmelstein et al.: U.S. per-capita admin $2,497 vs. $551 in Canada. A single payer eliminates most of this; my estimate from their numbers is that single payer would save on the order of $600 billion a year in administration alone, more than paying for covering everyone.

Remedy. Medicare for All: single public payer, comprehensive benefits, no premiums or deductibles, global hospital budgets, national drug formulary.

Tradeoff I concede. A roughly 10-point-of-GDP shift of spending onto the federal ledger (Mercatus, Brief #36) requires big broad-based taxes; the transition would eliminate hundreds of thousands of insurance and billing jobs.

Falsifiable prediction. If I'm right, a state that adopts a unified all-payer claims/billing system with standardized contracts (short of single payer) should see provider billing-cost shares drop measurably (>2 points of hospital operating expense) within 5 years.

---

Prof. Nkechi Adeyemi (#45, nursing · L)

Causal claim. The access crisis is partly manufactured by guild restrictions on who may deliver primary care. AAMC projects a shortage of up to 86,000 physicians by 2036 (Brief #38). Nurse practitioners with full practice authority deliver primary care of equal quality at lower cost, and the 2026 coverage losses (Brief #25) will hit hardest in rural and non-expansion areas (18.1% adult uninsured, Brief #21), which are exactly where NPs practice.

Evidence. AAMC shortage projection; NHIS state disparities; decades of observational work on NP care quality (I'll concede I am not bringing a single randomized trial to the table).

Remedy. Federal Medicaid/Medicare payment incentives for states to adopt full NP practice authority; restore the enhanced PTCs; fund NP and physician residency slots.

Tradeoff I concede. Some studies find NPs order more imaging/tests in some settings; savings on salaries may be partly offset by resource use.

Falsifiable prediction. States that grant full practice authority after 2026 should show higher primary-care visit rates among Medicaid adults and no increase in avoidable hospitalizations within 3 years relative to non-adopting states.

---

Prof. Priya Venkataraman (#19, inequality economics · L) — brief opening, drug pricing

Causal claim. Monopoly pricing of patented drugs is a transfer from sick people to shareholders with small innovation payoff at the margin. IRA negotiation delivered 22% net savings on round-1 drugs and ~44% on round 2, with semaglutide at $274 vs. $959 list (Brief #26), at a CBO-estimated cost of ~1% of new drugs over 30 years (Brief #27).

Remedy. Expand negotiation to more drugs sooner and extend negotiated prices to commercial plans.

Tradeoff I concede. Extending to commercial markets raises the innovation stakes considerably beyond what CBO scored for the Medicare-only program.

Falsifiable prediction. If CBO's elasticity is roughly right, FDA novel approvals averaged over 2027–2031 will not fall more than ~5% below the 2018–2025 average.

Stage 2: OPENING POSITIONS — Part 2 (Center bloc)

---

Prof. Hannah Okafor (#9, health economics · C)

(Speaking here as a participant, not as referee.)

Causal claim. The single largest fixable driver of excess U.S. spending is provider market power in commercial markets — above all hospitals. Private plans pay 254% of Medicare (Brief #13), outpatient facility services 289%. Monopoly hospitals charge 12% more than those with 4+ rivals and close-by mergers raise prices >6% (Cooper et al., Brief #12). CBO attributes commercial price levels primarily to market power, not to cost-shifting (Brief #14).

Evidence. As above, plus Peterson-KFF: ~80% of the U.S.–peer gap is inpatient and outpatient care (Brief #5).

Remedy. (1) Aggressive FTC and state merger enforcement including cross-market and physician-practice acquisitions; (2) ban anti-tiering / all-or-nothing contracting clauses; (3) site-neutral payment in Medicare; (4) consider a backstop cap on commercial prices only in markets that fail a concentration test.

Tradeoff I concede. Antitrust is slow and retrospective; most harmful mergers have already happened, and unwinding them is rare.

Falsifiable prediction. If market power is the main driver, commercial price growth in markets that adopt contract-clause bans or backstop caps should run at least 2 points/year below matched markets within 3 years.

---

Prof. Robert Chen (#42, health policy · C)

Causal claim. Medicare's payment rules actively subsidize consolidation: paying a hospital-owned outpatient department more than an independent physician office for the same service gives hospitals a reason to buy practices and relabel them.

Evidence. CBO scores site-neutral options at ~$4B (drug administration, off-campus), ~$39B (all off-campus HOPD), ~$102B (on-campus services commonly delivered elsewhere) over 10 years (Brief #15). Combined, we are looking at well over $150 billion in savings.

Remedy. Enact the off-campus and on-campus site-neutral policies in stages, with a carve-out/transition for rural and sole-community hospitals.

Tradeoff I concede. MedPAC's approach cuts OPPS hospital Medicare revenue ~3.8% (Brief #15) — for some safety-net hospitals, that's the whole operating margin.

Falsifiable prediction. Within 5 years of full site-neutral implementation, the share of office-based E&M and drug-administration services billed as HOPD should stop rising and physician-practice acquisitions by hospitals should slow.

---

Prof. Grant Albrecht (#6, antitrust/IO · C)

Causal claim. Price transparency, as currently implemented, has been a regulatory failure — only about one in five hospitals complies — and even perfect compliance would not discipline prices much, because the relevant buyers (insurers) already know the prices and patients don't shop (Brot-Goldberg, Brief #17).

Evidence. PRA's compliance reviews; Brot-Goldberg: zero price-shopping learning after two years; IO theory: transparency in concentrated markets can soften competition.

Remedy. Stop sinking political capital into consumer-facing transparency; use transparency data as an enforcement input for antitrust and for employer purchasers (reference pricing, direct contracting).

Tradeoff I concede. Employer-side reference pricing only works for large self-insured firms; small-group markets get little.

Falsifiable prediction. If transparency's value is primarily as an enforcement/purchasing input, we should see employers using machine-readable-file data to renegotiate before we see any measurable consumer shopping — i.e., no detectable change in patient choice of facility within 3 years, but measurable narrowing of price dispersion among large self-insured purchasers.

---

Prof. Thomas Reilly (#44, primary care · C) — brief opening, coverage

Causal claim. Coverage is a financial-protection product first and a health product second. Oregon (Brief #19): catastrophic spending virtually eliminated, depression reduced, no significant 2-year change in BP/cholesterol. So the case for the enhanced PTCs and for protecting Medicaid rests mainly on financial security and mental health, and we should say so honestly.

Remedy. Restore enhanced PTCs with an income cap and anti-fraud provisions; implement Medicaid work requirements (now law) via automated data matching to minimize procedural disenrollment.

Tradeoff I concede. Restored eAPTCs are expensive and mostly subsidize people already insured.

Falsifiable prediction. Medical-debt collections (Brief #39) in states with the largest 2026–2028 coverage losses will rise relative to other states within 2 years.

Stage 2: OPENING POSITIONS — Part 3 (Right bloc)

---

Prof. Douglas Wren (#2, public finance · R)

Causal claim. Open-ended federal matching and subsidy structures drive spending and crowd out private coverage. The 2025 reconciliation law's Medicaid provisions are mainly about program integrity — removing people who are ineligible or who are able-bodied and not working — and the resulting coverage loss among people who actually want and qualify for coverage will be small. Medicaid's health returns are modest anyway: the only randomized trial (Oregon) found no significant effect on physical health.

Evidence. CBO: ~$1.06T federal savings over 10 years (Brief #22), about a third of it from work requirements; Oregon RCT (Brief #19); Census 2025 uninsured rate unchanged (Brief #20).

Remedy. Keep the law's Medicaid reforms; convert the expansion match toward per-capita caps; let the enhanced PTCs stay expired.

Tradeoff I concede. Some eligible people will lose coverage from paperwork, and states' IT systems are not all ready.

Falsifiable prediction. If I am right, when work requirements start (after Dec 31, 2026), employment among expansion adults will rise and the uninsured rate among 19–64-year-olds will rise by less than 1.5 points by 2029.

---

Prof. Alan Whitmore (#46, pharmacology · C-R)

Causal claim. Drug prices are the one area where the U.S. pays more and gets something for it: a disproportionate share of global pharmaceutical R&D returns. The IRA's negotiation program taxes that return, and its 9-year clock for small molecules (vs. 13 for biologics) will specifically starve pills — the cheap-to-distribute modality.

Evidence. Philipson et al. (Brief #28) on the small-molecule "pill penalty." CBO's 13-of-1,300 (Brief #27) assumes a low R&D elasticity. And the round-1 "22% savings" is unimpressive: it is a discount off list prices that nobody actually paid.

Remedy. Pass the EPIC Act (equalize small molecules at 13 years); exclude orphan and follow-on indications more broadly; pursue international burden-sharing via trade policy rather than domestic price setting.

Tradeoff I concede. Equalizing the clock reduces federal savings.

Falsifiable prediction. Within 5 years (by 2031), the share of new Phase I starts by U.S.-based companies that are small molecules will fall at least 5 points relative to 2019–2022.

---

Prof. Walter Pruitt (#8, law & economics · Lib)

Causal claim. Third-party payment insulates consumers from prices; tax-subsidized employer insurance drives overinsurance; and hospitals charge private payers more because government programs underpay — cost shifting. Put money in patients' hands (HSAs, deductibles) and prices will fall as consumers shop.

Evidence. RAND HIE (Brief #18): cost sharing cut spending 20–30% without average health harm; Swiss system (Brief #6) runs 22% out-of-pocket with universal coverage and high satisfaction.

Remedy. Cap the employer exclusion; expand HSA eligibility and contribution limits; deregulate certificate-of-need and scope-of-practice; convert Medicare to premium support.

Tradeoff I concede. Deductibles bite hardest on the chronically ill and poor, the group RAND found was harmed.

Falsifiable prediction. In markets with high HSA/HDHP penetration and good transparency tools, shoppable-service prices (MRI, colonoscopy) should fall relative to low-penetration markets within 3 years.

---

Prof. Raymond Kessler (#18, macro · R) — brief opening

Causal claim. The "U.S. spends double" headline is partly a statement about U.S. income: richer societies spend more on services generally, and health care behaves like a normal-to-luxury good.

Remedy. Focus policy on value per dollar (e.g., site-neutral, competition) rather than on hitting a GDP-share target.

Tradeoff I concede. Even adjusted for income, the U.S. is likely above trend.

Falsifiable prediction. A cross-country regression of health spending on household consumption per capita should put the U.S. far closer to the line than a regression on GDP per capita.

Stage 3: CROSS-EXAMINATION — Part 1 (Left openings challenged)

---

X1. Kessler (#18, R) → Mercer (#41, L): "prices explain essentially all of the gap"

Kessler: Diane, your own sources don't say "all." Peterson-KFF's decomposition (Brief #5) is a category breakdown — hospital/outpatient vs. admin vs. drugs — not a price-vs-quantity breakdown. And CMS's actuaries say 2024 per-capita growth was 3.6 points use/intensity vs. 2.5 points price (Brief #10). Cooper et al. find within-U.S. variation is half quantity (Brief #11). Utilization is not irrelevant; the U.S. has high volumes of specific high-tech services even if doctor visits and bed-days are low.

Mercer: The growth number for one year is not the level gap. Papanicolas compared levels across 11 countries and found similar utilization; that's the relevant comparison for "why do we spend double."

Kessler: Then say "prices explain most of the level gap in hospital and physician care." That's defensible. "Essentially all" is not, and "utilization is not a factor" is contradicted by CMS for the spending trajectory we're actually living through.

Mercer: I'll take the narrower wording on the record: prices are the dominant driver of the U.S.–peer level gap; use and intensity matter for recent growth. The policy implication is unchanged — you can't fix the level gap by cutting visits.

---

X2. Whitmore (#46, C-R) → Mercer (#41, L): "the life-expectancy gap is fundamentally about lack of universal coverage"

Whitmore: Your causal chain has a hole. The best causal evidence on coverage and physical health — Oregon — found no significant 2-year effect on BP, cholesterol or cardiovascular risk (Brief #19). The peer gap is concentrated in external causes — overdoses, injuries — plus circulatory and metabolic disease (Brief #31); the U.S. actually has among the lowest cancer mortality, which is the disease most dependent on high-end medical care. Overdose deaths just fell 26% in one year (Brief #32) with no change in coverage policy. Coverage is not the lever for most of this gap.

Mercer: Oregon was two years and underpowered for mortality, and quasi-experimental expansion studies do find mortality effects. But — conceded — I overstated "fundamentally." Overdoses, firearms and transport deaths are a large share of under-65 excess mortality (Bor et al., Brief #33, 49% under 65) and are not primarily coverage problems. Revised claim: coverage contributes to the gap, especially via chronic-disease management, but it is one of several drivers and probably not the largest. My prediction stands.

---

X3. Wren (#2, R) → Delgado-Finch (#7, Soc): single payer and the "$600 billion" — extended exchange

Wren (round 1): Rosa, your $600B a year is your arithmetic, not anyone's score. Himmelstein's 34.2% (Brief #34) includes provider-side billing and a broad definition the OECD doesn't use (7.6%, Brief #5). CBO — which actually modeled five single-payer designs — found national health spending could fall $0.7T or rise $0.3T in 2030 (Brief #35), and the savings in the favorable cases come overwhelmingly from paying providers less, not from admin. Mercatus finds the plan requires paying providers >40% below private rates (Brief #36). Your savings are a pay cut dressed up as efficiency.

Delgado-Finch (round 1): CBO's own favorable cases show lower total spending with universal coverage. Every other rich country pays providers less. A "pay cut" for hospitals charging 254% of Medicare (Brief #13) is precisely the point.

Wren (round 2): Then own it. CBO also says demand would outpace supply and generate longer waits and unmet demand, "particularly under scenarios featuring lower cost-sharing and payment rates" (Brief #35). You can't have zero cost sharing, Medicare-level rates, and no queues. Canada, your admin exemplar, has notorious waits.

Delgado-Finch (round 2): Waits are a supply-side choice — fund residencies, expand scope of practice (I'm with Adeyemi). And the current system rations by price: 14 million adults with >$1,000 in medical debt (Brief #39), 26.7 million uninsured all year (Brief #20).

Wren (round 3): Rationing by price vs. rationing by queue is a real tradeoff — I'll grant that the U.S. rations by price. What I won't grant is that single payer is self-financing through admin savings. That was your claim.

Delgado-Finch (round 3): On the specific number: I withdraw the "$600 billion a year in administration alone." I derived it from Himmelstein's broad 34.2% vs. Canada's 17%, which assumes the U.S. could hit Canadian admin shares immediately and that nothing else changes. CBO's modelled range (−$0.7T to +$0.3T total) is the better evidence, and it shows savings depend mostly on payment rates. My position is now: single payer can plausibly lower national spending if it sets rates near Medicare and accepts some queueing risk; admin savings are real but secondary. I still prefer it on equity grounds, and I note CBO's own favorable cases are cheaper for the nation than the status quo.

Wren (closing): Agreed that's a fair restatement. We disagree about whether federal taxes of ~10–12% of GDP (Mercatus) are worth it; that's values, not facts.

---

X4. Pruitt (#8, Lib) → Adeyemi (#45, L): scope of practice

Pruitt: Odd alignment — I agree with your remedy. My challenge is to your evidence: you said NPs deliver "equal quality at lower cost," then conceded you have no RCT. The better argument is a liberty-and-competition one: licensing boards controlled by incumbents shouldn't decide who competes with them.

Adeyemi: The observational literature across dozens of states is consistent. But fine: I'll restate it as NP full practice authority expands access in shortage areas; quality effects appear small in observational work but aren't settled, and resource-use effects are mixed.

Pruitt: Then we have the same policy with different reasons, which is a good sign.

---

X5. Whitmore (#46, C-R) → Venkataraman (#19, L): IRA innovation

Whitmore: CBO's 1% rests on an assumed elasticity of R&D to expected revenue. Your extension to commercial markets would multiply the revenue hit severalfold; CBO didn't score that. And the small-molecule clock distortion (Brief #28) is real regardless of the aggregate.

Venkataraman: Agreed CBO didn't score commercial extension — I conceded that in my opening. On the pill penalty: I'm open to equalization if it's paid for by bringing negotiation forward for biologics rather than delaying it for pills.

Whitmore: That's a trade I'd consider. But note that your 44% semaglutide-round figure is relative to net, which is the correct basis — and so is round 1's 22%, which I'll address when the referees get to me.

Stage 3: CROSS-EXAMINATION — Part 2 (Center and Right openings challenged)

---

X6. Delgado-Finch (#7, Soc) → Okafor (#9, C): antitrust is too slow

Delgado-Finch: You admit the harmful mergers already happened. RAND's state range (Brief #13) — from under 200% of Medicare in Michigan and Massachusetts to over 300% in California, Florida, New York — isn't going to be fixed by FTC suits. Why not all-payer rate setting everywhere, as Maryland does?

Okafor: Because the evidence for market power as the driver (Cooper, CBO; Briefs #12, #14) also tells us where the problem is: concentrated markets. A national rate cap applies a remedy for monopoly to competitive markets too, killing the price signal that attracts new entrants. My backstop cap is targeted at markets failing a concentration test. And Cooper found concentrated insurer markets have lower hospital prices — a bilateral-bargaining point that cuts against pure consumer-choice solutions and against assuming only a government payer can bargain.

Delgado-Finch: A backstop cap is still a price cap. Welcome to the club.

Okafor: A targeted one, yes. I'll wear it.

---

X7. Wren (#2, R) → Chen (#42, C): site-neutral "well over $150 billion"

Wren: I support site-neutral. But Robert, you summed CBO's three options ($4B + $39B + $102B) as if additive. The $4B drug-administration policy is a subset of the $39B off-campus policy. Stacking overcounts.

Chen: Fair. Off-campus all services ($39B) plus on-campus ($102B) is ~$141B if scored together, and CBO hasn't scored that exact combination. Amended: "on the order of $140B over 10 years if both off- and on-campus policies were enacted, subject to interaction effects; no single official score for the combination."

---

X8. Venkataraman (#19, L) → Albrecht (#6, C): transparency "one in five comply"

Venkataraman: Grant, your 21% compliance number is out of date. PRA's latest review found 49.4% fully compliant — the highest ever (Brief #16). And PRA's test is stricter than CMS's.

Albrecht: Accepted — I cited the prior review. The trajectory is better than I said. My substantive claim — that we lack evidence consumer-facing transparency lowers prices, and that the main value is as an input to purchasers and enforcers — doesn't depend on the compliance rate.

Venkataraman: On that I partly agree. But employer purchasers are exactly who needs the data, which argues for more enforcement, not less political capital.

Albrecht: Then we agree on enforcement and disagree on the marketing.

---

X9. Wren (#2, R) → Reilly (#44, C): eAPTCs

Wren: You conceded restored eAPTCs mostly subsidize people already insured. CBO attributes 4.2M of 2034 uninsurance to expiration (Brief #23) — against a cost that was in the hundreds of billions. That's an expensive way to cover people.

Reilly: Cost per newly insured is high, yes. But the financial-protection value (Oregon, Brief #19) accrues to the already-insured too: marketplace enrollees' net premium payments rose ~58% on average in 2026 (Brief #25). That's exactly the catastrophic-exposure risk Oregon showed coverage removes. An income cap is my compromise.

---

X10. Mercer (#41, L) → Wren (#2, R): "coverage loss will be small"

Mercer: CBO scores the enacted law at +10 million uninsured in 2034 (Brief #22). That's not small. And you cite the unchanged 2025 Census rate (Brief #20) as reassurance, but the work requirements don't begin until after Dec 31, 2026. The 2025 number is a baseline, not an outcome.

Wren: CBO's number is a projection built on assumptions about procedural churn — people who are eligible or would comply but lose coverage due to paperwork. That's an implementation problem, not a design flaw.

Mercer: Then it's still coverage loss! Arkansas's 2018 work requirement removed ~18,000 people before a court halted it, with no detectable employment gain — I'll have the referees check that, I don't have the link in front of me.

Wren: Look — I'll narrow my claim. CBO's 10M is the best available estimate and I can't cite anything showing it is too high. I'll restate: most of the projected loss is procedural, which is a reason to implement with automated verification, not a reason to repeal. On Oregon, I'll also concede I cited it selectively — it found large reductions in catastrophic spending and depression.

---

X11. Venkataraman (#19, L) → Whitmore (#46, C-R): "22% is off list prices nobody paid"

Venkataraman: Alan, KFF is explicit: round 1's 22% is the reduction from existing net prices — after rebates (Brief #26). Round 2's ~44% is also net-based. The discounts off list were larger. Your claim is backwards.

Whitmore: I was thinking of CMS's list-price comparisons for individual drugs (e.g., the 38–79% list discounts widely reported). You're right on the aggregate: 22% is net. I retract that sentence. My core argument — the 9-year small-molecule clock distorts R&D — doesn't depend on it.

Venkataraman: And the evidence for that is industry-affiliated modeling the referees couldn't pin to a number (Brief #28), vs. CBO's 1% (Brief #27).

Whitmore: CBO also assumed modest elasticity. We'll know from Phase I starts by 2031 — that's why I made a falsifiable prediction.

---

X12. Okafor (#9, C) and Adeyemi (#45, L) → Pruitt (#8, Lib): consumer shopping and cost-shifting

Okafor: Walter, two problems. First, CBO found the Medicare/Medicaid share of a provider's patients is not related to higher commercial prices (Brief #14). Cost-shifting is not the story; market power is. Second, Brot-Goldberg found HDHP enrollees cut spending 12–14% entirely via quantity, with no price shopping after two years, and cut preventive care (Brief #17).

Adeyemi: And RAND — your own citation — found cost sharing cut effective and ineffective care alike and harmed the poorest, sickest 6% (Brief #18).

Pruitt: On cost-shifting: CBO's finding is solid and I'll drop it. On shopping: Brot-Goldberg studied one firm, pre-transparency-rule, with little shopping infrastructure. My prediction (shoppable-service prices fall in high-HSA markets) is precisely the test.

Okafor: But Albrecht's point stands: patients spend most dollars after hitting the deductible or in emergencies. Shoppable services are a minority of spending.

Pruitt: Granted: consumer shopping is at most a partial discipline. I'll amend: cost sharing reliably lowers quantity; evidence that it lowers prices is weak so far; its best use is paired with tiered or reference-priced networks that let insurers/employers do the shopping. I also note Switzerland pairs 22% OOP with universal, community-rated coverage (Brief #6) — cost sharing and universality aren't enemies.

---

X13. Brandt (#57, referee) → Kessler (#18, R): income-adjusted spending

Brandt: Raymond, your prediction is testable but you haven't cited a source for it in this thread, and the panel could not fetch one within budget. Also, you conceded the U.S. is "likely above trend" even adjusted.

Kessler: Correct — it's a hypothesis with a literature behind it, not a fact in the brief. I'll leave it as a claim to be rated Contested/unsourced.

Stage 4: REFEREE FACT-CHECK

Brandt (#57) · Takahashi (#17) · Okafor (#9, recused on her own claims — rows 15–18, 48 rated by Brandt/Takahashi alone)

Ratings: Supported = matches a cited primary/credible source · Contested = credible evidence on both sides, or plausible but unsourced in this thread · Unsupported = not verified / not backed by cited evidence · Wrong = contradicted by the cited evidence. Numbers in brackets are Brief items.

# · Speaker · Claim (as made) · Rating · Basis
1 · Mercer · U.S. $14,775 vs. $7,860 per capita (2024) · Supported · Peterson-KFF [4]
2 · Mercer · Prices explain "essentially all" of gap; utilization "not a factor" · Wrong (as stated) · CMS 2024 growth: use/intensity 3.6 pts vs price 2.5 [10]; Cooper: within-US variation half quantity [11]. Level-gap version is Supported [8,9]
3 · Mercer · Private plans pay 254% of Medicare · Supported · RAND 5.1 [13]
4 · Mercer · 1.09M excess deaths 2021, ~half under 65 · Supported · Bor et al. [33]
5 · Mercer · LE gap "fundamentally" due to lack of universal coverage · Unsupported · Gap concentrated in external/circulatory/metabolic causes [31]; Oregon null on physical markers [19]; overdoses fell 26% without coverage change [32]
6 · Delgado-Finch · Admin = 34.2%, $812B; Canada 17% · Supported (definition caveat) · Himmelstein 2020 [34]; OECD narrow = 7.6% [5]
7 · Delgado-Finch · Single payer saves ~$600B/yr on admin alone; self-financing · Unsupported · No score supports it; CBO total NHE range −$0.7T to +$0.3T, savings mainly from payment rates [35]
8 · Delgado-Finch · CBO's favorable single-payer cases lower national spending · Supported · CBO 2020 [35]
9 · Delgado-Finch · ~10 pts of GDP moves to federal ledger · Supported · Mercatus: 10.7% of GDP (2022) → 12.7% (2031) [36]
10 · Adeyemi · AAMC: shortage up to 86,000 by 2036 · Supported · AAMC [38]
11 · Adeyemi · NPs deliver equal quality at lower cost · Contested · No study verified in-thread; speaker conceded mixed resource-use findings
12 · Adeyemi · Non-expansion states 18.1% adult uninsured · Supported · NHIS 2025 [21]
13 · Venkataraman · Round 1 22% net; round 2 ~44%; semaglutide $274 vs $959 · Supported · KFF; BioPharma Dive [26]
14 · Venkataraman · CBO: ~1% fewer drugs over 30 yrs · Supported · CBO via KFF [27]
15 · Okafor · 254% overall; outpatient facility 289% · Supported · RAND [13]
16 · Okafor · Monopoly +12%; close mergers >6% · Supported · Cooper et al. [12]
17 · Okafor · CBO: market power, not cost-shift · Supported · CBO 57422 [14]
18 · Okafor · ~80% of US–peer gap in inpatient/outpatient care · Supported (2021 data) · Peterson-KFF [5]
19 · Chen · CBO: $4B / $39B / $102B site-neutral options · Supported · KFF citing CBO [15]
20 · Chen · Combined "well over $150B" · Wrong · Double-counts $4B inside $39B; no combined CBO score. Amended ~$141B = Contested
21 · Chen · MedPAC: −3.8% OPPS Medicare revenue · Supported · [15]
22 · Albrecht · "About one in five hospitals comply" · Wrong (outdated) · PRA latest 49.4% [16]
23 · Albrecht · No consumer price-shopping learning in HDHP · Supported · Brot-Goldberg [17]
24 · Albrecht · Consumer-facing transparency doesn't lower prices · Contested · Absence of evidence, not evidence of absence; no causal study in-thread [C6]
25 · Reilly · Oregon: catastrophic spending ~eliminated, depression down, no sig. BP/cholesterol effect · Supported · NBER OHIE [19]
26 · Reilly · Restored eAPTCs mostly subsidize the already-insured · Contested · Plausible given 4.2M vs ~20M+ enrollees [23,25], no cost-per-newly-insured source in-thread
27 · Wren · Coverage loss from 2025 law's Medicaid provisions "will be small" · Wrong · CBO: +10M uninsured 2034 (enacted law) [22]
28 · Wren · ~$1.06T federal savings; ~1/3 from work requirements · Supported · $325.6B / $1.06T ≈ 31% [22]
29 · Wren · Medicaid's health returns modest (Oregon) · Contested · Selective: Oregon also shows large financial & mental-health gains [19]; quasi-experimental mortality literature disagrees [C3]
30 · Wren · Census 2025 uninsured unchanged · Supported (but uninformative on the law) · Census [20]; provisions mostly not yet in effect [C7]
31 · Whitmore · Round 1 "22%" is off list prices nobody paid · Wrong · KFF: 22% vs. existing net prices [26]
32 · Whitmore · CBO elasticity is low; 9-yr clock distorts small-molecule R&D · Contested · CBO [27] vs. Philipson et al. [28]; no outcome data yet
33 · Whitmore · U.S. cancer mortality among lowest; gap in external/circulatory causes · Supported · Peterson-KFF [31]
34 · Whitmore · Overdose deaths fell ~26% · Supported · NCHS: −26.2% rate, 79,384 deaths (2024) [32]
35 · Pruitt · RAND: 20–30% lower spending, no average harm · Supported (w/ poor-sick exception) · RAND HIE [18]
36 · Pruitt · Hospitals charge private payers more due to gov't underpayment (cost-shift) · Wrong · CBO: public-payer share unrelated to commercial prices [14]
37 · Pruitt · HSAs/deductibles will lower prices via shopping · Unsupported · Brot-Goldberg: quantity only, no shopping [17]; RAND [18]
38 · Pruitt · Switzerland 22% OOP with universal coverage · Supported · Commonwealth Fund [6]
39 · Kessler · U.S. spending largely reflects high income/consumption · Contested · Unsourced in thread; speaker concedes U.S. above trend
40 · Kessler · CMS: use/intensity 3.6 pts vs price 2.5 pts (2024) · Supported · [10]
41 · Kessler · Cooper: within-US variation half quantity · Supported · [11]
42 · Mercer · Arkansas 2018 work requirement: ~18,000 lost coverage, no employment gain · Unsupported (unverified here) · Panel could not fetch a source within budget; widely reported, but not verified in this thread
43 · Wren · CBO: 4.2M uninsured from eAPTC expiration · Supported · [23]
44 · Reilly · Marketplace net premium payments +58% in 2026 · Supported · KFF [25]
45 · Delgado-Finch · 14M adults >$1,000 medical debt; 26.7M uninsured all year · Supported · KFF [39]; Census [20]
46 · Wren · CBO: single payer → more unmet demand/waits · Supported · CBO [35]
47 · Whitmore · Individual list discounts "38–79%" · Unsupported (unverified here) · Not in fetched sources
48 · Okafor · Concentrated insurer markets → lower hospital prices · Supported · Cooper et al. [12]

Tally (48 claims): Supported 31 · Contested 6 · Unsupported 5 · Wrong 6

Referee comment (Takahashi): The errors are bipartisan. The Left overstated "prices explain everything" and "coverage explains the life-expectancy gap"; the Right overstated "coverage losses will be small" and "cost-shifting"; the Center double-counted site-neutral savings and cited stale compliance data. The most consequential correction is #36: cost-shifting is a common argument against Medicare rate cuts and CBO's evidence does not support it.

---

Retractions and amendments on the record

• Mercer (#2, #5, #42): "Amended: prices dominate the level gap; use/intensity drive much recent growth. Coverage is one driver of the LE gap, not the fundamental one. Arkansas figure withdrawn from the record until sourced."
• Delgado-Finch (#7): "Retracted the $600B figure (see X3). Single payer's net savings depend on payment rates; I accept CBO's range as the governing evidence."
• Chen (#20): "Amended to ~$141B, no combined official score."
• Albrecht (#22): "Retracted 'one in five'; compliance is ~49% on PRA's strict test."
• Wren (#27, #29): "Retracted 'small.' CBO's 10M is the best estimate; my claim is that most of it is procedural and should be minimized administratively. I cited Oregon selectively."
• Whitmore (#31, #47): "Retracted the list-vs-net claim. Withdraw the 38–79% figure pending a source."
• Pruitt (#36, #37): "Retract cost-shifting. Amend: cost sharing reliably reduces quantity; price effects unproven; pair with reference-priced networks."
• Adeyemi (#11), Kessler (#39): accept Contested ratings; both claims to be treated as hypotheses.

Stage 5: STEELMAN

---

Left steelmans the Right — written by Prof. Delgado-Finch (#7) and Prof. Mercer (#41)

"The strongest conservative case is not 'coverage doesn't matter.' It is this: the U.S. cost problem is overwhelmingly a commercial-price problem driven by provider market power (CBO, Cooper), and a government that sets prices will be captured by the same providers — witness how hospital lobbying has blocked site-neutral payment for a decade. Open-ended federal matching (Medicaid's FMAP, uncapped PTCs) lets states and insurers push costs onto federal taxpayers, and the enhanced PTCs sent subsidies to households far above 400% FPL at high cost per newly insured person. On drugs, the U.S. finances a disproportionate share of global pharmaceutical innovation; a Medicare-only negotiation program with a 9-year clock for pills may be modest in aggregate (CBO ~1%) but distorts which drugs get made, and those losses are invisible and long-delayed. On outcomes, the American life-expectancy gap is concentrated in overdoses, injuries, violence and metabolic disease — problems that more insurance does not fix, as the Oregon RCT's null physical-health results suggest. Finally, cost sharing demonstrably reduces use without average harm (RAND), and Switzerland shows a universal system can run on private insurers and 22% out-of-pocket spending. The Right's program — competition, site-neutral, reference pricing, integrity in means-tested programs, protecting innovation — targets real inefficiencies without a federal takeover whose own score (CBO) includes longer waits."

Right reply — Wren (#2) and Whitmore (#46): Accepted as fair. One correction from Wren: "Our case on Medicaid is also about who decides: per-capita caps give states budget certainty and flexibility; it is not only a fiscal-leakage argument." Whitmore adds: "I'd emphasize that we support competition policy against hospitals as strongly as the Center does — that should be in the steelman." Delgado-Finch: "Accepted; I put it first."

---

Right steelmans the Left — written by Prof. Pruitt (#8) and Prof. Kessler (#18)

"The strongest left case: Americans are not overusing care; they are overpaying for it — private plans pay hospitals 2.5x Medicare, and the peer gap sits in hospital and physician prices. Market competition cannot fix this because the key markets are local monopolies, patients cannot shop in emergencies or after hitting deductibles (Brot-Goldberg found zero price-shopping learning), and even 'managed competition' countries like Switzerland and the Netherlands rely heavily on regulated prices, risk equalization and mandatory community rating — none of which is laissez-faire. Every other rich country uses some form of monopsony or all-payer price regulation, and they spend ~half as much per person. Meanwhile the U.S. rations by price: 26.7 million uninsured, 14 million adults owing more than $1,000 in medical debt, and CBO projecting 10 million more uninsured by 2034 from the 2025 law and 4.2 million more from subsidy expiration — mostly through paperwork churn, not through anyone choosing work. Coverage's best-proven benefits — near-elimination of catastrophic expenditure and reduced depression (Oregon) — are real welfare gains even if blood pressure didn't move in two years. And the IRA shows public negotiation can cut net prices 22–44% with an estimated ~1% innovation cost."

Left reply — Venkataraman (#19) and Mercer (#41): Accepted as fair, with one correction from Mercer: "Add that single payer and all-payer rate-setting also compress administrative costs — even on the OECD's narrow measure, the U.S. share is double peers' (7.6% vs 3.8%). We concede, per the referees, that this is secondary to price." Pruitt: "Accepted."

---

Center steelmans the Left-and-Right skeptics of incrementalism — Prof. Albrecht (#6)

"Both flanks argue the Center's menu — site-neutral, transparency, antitrust — is too small. The Left: $39–141B over ten years is a rounding error against $5.3 trillion per year; antitrust cannot unwind existing monopolies; only rate setting can close a 254%-of-Medicare gap. The Right: incremental Medicare rules invite gaming (hospitals will relabel services), transparency without consumer incentive is theater, and the real lever is the tax exclusion that makes insurance the default way to buy routine care."

Left and Right replies: Delgado-Finch: "Accepted." Pruitt: "Accepted — and I'd add that CON laws are a state-level barrier the Center tends to ignore." Albrecht: "Fair addition."

Stage 6: REVISED PROPOSALS

Drafted by Okafor (#9) and Chen (#42) with amendments from Wren (#2), Delgado-Finch (#7), Pruitt (#8), Whitmore (#46), Adeyemi (#45). Scores are cited where they exist; "no official score" where none was found.

---

P1. Site-neutral Medicare payment, staged

• Mechanism: Pay the physician-office/ASC rate for (a) all services in off-campus HOPDs, then (b) on-campus services commonly delivered in offices, phased over 4 years; hold-harmless for rural, critical-access, and sole-community hospitals.
• Score: CBO ~$39B/10 yrs (all off-campus) and ~$102B/10 yrs (on-campus subset), scored separately; no official combined score [15].
• Precedent: BBA 2015 applied site-neutral rates to new off-campus HOPDs; 2019 CMS rule extended clinic-visit alignment to all off-campus HOPDs [15]. Result: implemented without documented access collapse (no rigorous outcome evaluation fetched here).
• Key risk: Revenue hit (~3.8% of OPPS Medicare revenue per MedPAC) concentrated at safety-net hospitals; hospitals may shift billing to evade.

P2. Enforce price transparency in dollars, and route the data to purchasers and enforcers

• Mechanism: Require dollar amounts (no algorithms/percentages), escalate civil penalties for noncompliance, standardize machine-readable files, and give FTC/state AGs and employer plan fiduciaries a standardized feed.
• Score: No official score (primarily regulatory; minimal federal cost).
• Precedent: Federal rule since Jan 2021; compliance rose from 21% to 49.4% on PRA's test [16]. Evidence that consumer-facing transparency lowers prices is lacking [C6].
• Key risk: In concentrated markets, published prices may facilitate tacit coordination rather than competition.

P3. Competition package: merger scrutiny + ban anticompetitive contract clauses

• Mechanism: Lower HSR reporting thresholds for physician-practice and cross-market hospital acquisitions; federal ban on anti-tiering, anti-steering, all-or-nothing and gag clauses in commercial contracts; fund FTC health-care enforcement.
• Score: No official score for the package.
• Precedent: Cooper et al.: close-by mergers raised prices >6% [12]; CBO identifies market power as main driver [14]. Several states have enacted clause bans (specific states/outcomes not verified in this thread).
• Key risk: Retrospective; does little about existing monopolies; litigation costs.

P4. Backstop cap on commercial hospital prices in concentrated markets

• Mechanism: In markets above a concentration threshold, cap in-network and out-of-network commercial hospital prices at 200% of Medicare, phased down from current levels over 5 years.
• Score: No official CBO score for this specific design.
• Precedent: Swiss and Dutch systems combine private insurers with regulated prices [6]; Maryland's all-payer system (not verified in this thread). U.S. commercial average currently 254% of Medicare [13].
• Key risk: Hospital closures/quality cuts in high-cost markets; caps become floors; political capture of the cap level.

P5. Restore enhanced premium tax credits, restructured

• Mechanism: Reinstate eAPTC schedule for 3 years with a hard income cap (e.g., 600% FPL), $0-premium plans replaced with a minimum premium, and income-verification anti-fraud rules.
• Score: No official CBO score for this exact design located; CBO attributes ~4.2M uninsured in 2034 to expiration [23].
• Precedent: Under eAPTCs marketplace enrollment grew from 16.2M (2023) to 21.1M (2024) [2] and 22.1M (2025); after expiration it fell to 19.2M by Feb 2026 [25].
• Key risk: Cost per newly insured is high; subsidizes coverage many would buy anyway.

P6. Implement the 2025 law's Medicaid work requirements via automated verification

• Mechanism: Require states to use ex parte data (wage records, SNAP/TANF compliance, disability data) before requesting documentation; delay disenrollment penalties in any state until its verification system is certified by CMS.
• Score: No official score; would reduce the law's savings to the extent it reduces procedural disenrollment (CBO's $325.6B work-requirement savings [22] depend largely on coverage loss).
• Precedent: Arkansas 2018 (outcome not verified in this thread; Mercer's figures withdrawn); Oregon shows coverage lowers catastrophic spending [19].
• Key risk: Reduces budget savings; Right sees it as a backdoor delay, Left as insufficient.

P7. EPIC Act: equalize small-molecule negotiation eligibility at 13 years

• Mechanism: Move small-molecule drugs from 9 to 13 years post-approval before negotiation eligibility.
• Score: No official CBO score located in this thread; reduces IRA savings (original negotiation score ~$98.5B/10 yrs [27]).
• Precedent: None — IRA prices only took effect in 2026 [26].
• Key risk: Gives up savings on the basis of contested innovation modeling [28] vs. CBO [27].

P8. Workforce: NP full practice authority incentive + residency expansion

• Mechanism: Bonus Medicaid FMAP (e.g., +1 point on primary care) for states granting NP full practice authority; fund additional Medicare GME slots targeted to primary care and rural areas.
• Score: No official score for this package.
• Precedent: AAMC projects shortage up to 86,000 by 2036 [38]; states vary in NP authority (quality evidence Contested, row 11).
• Key risk: Uncertain quality/resource-use effects; GME slots take ~7+ years to yield practicing physicians.

(Medicare for All / single payer was debated but not put to a vote as a standalone reform by agreement of the moderator; see Verdict.)

Stage 7: RECORDED VOTE

Blocs: Left 34 · Center 33 · Right 32 (moderator #100 abstains). Consensus requires ≥60% in every bloc (Left ≥21, Center ≥20, Right ≥20).

# · Proposal · Left yes · Center yes · Right yes · Consensus
P1 · Staged site-neutral Medicare payment · 24 (70.6%) · 29 (87.9%) · 23 (71.9%) · YES
P2 · Dollar-price transparency enforcement + data to purchasers/enforcers · 28 (82.4%) · 30 (90.9%) · 27 (84.4%) · YES
P3 · Competition package (merger scrutiny + contract-clause bans) · 30 (88.2%) · 27 (81.8%) · 21 (65.6%) · YES
P4 · Backstop cap on commercial hospital prices (200% Medicare, concentrated markets) · 30 (88.2%) · 17 (51.5%) · 5 (15.6%) · NO
P5 · Restore restructured enhanced PTCs (3 yrs, income cap) · 33 (97.1%) · 22 (66.7%) · 8 (25.0%) · NO
P6 · Medicaid work requirements via automated verification; delay penalties until systems certified · 26 (76.5%) · 26 (78.8%) · 17 (53.1%) · NO (Right 3 short)
P7 · EPIC Act (small molecules to 13 years) · 6 (17.6%) · 16 (48.5%) · 27 (84.4%) · NO
P8 · NP full-practice incentive + primary-care/rural GME slots · 22 (64.7%) · 25 (75.8%) · 23 (71.9%) · YES

Consensus reforms: P1, P2, P3, P8. Near-miss: P6 (Right 53%).

Notes on plausibility: Ten Left members voted no on P1 over safety-net revenue exposure despite the rural hold-harmless. Eleven Right members voted no on P3 as regulatory overreach into private contracting. P6 split the Right between those who saw automated verification as sound administration and those who saw the certification delay as a backdoor repeal.

---

Vote explanations

Prof. Walter Pruitt (#8, Lib) — P1 yes, P2 yes, P3 no, P4 no, P8 yes.
"Site-neutral removes a government-created subsidy for consolidation — that's deregulation, not regulation. I voted no on P3 because contract-clause bans are the government rewriting private contracts. What would change my mind: evidence that clause bans in the states that enacted them lowered commercial prices by more than a couple of points without reducing network breadth."

Prof. Rosa Delgado-Finch (#7, Soc) — P1 yes, P3 yes, P4 yes, P5 yes, P7 no.
"I voted for the incremental package while believing it is too small; ~$141B over a decade is about 0.3% of a single year's NHE. What would change my mind on single payer: a CBO or equivalent score showing that a Medicare-rate all-payer system with private insurers achieves the same total-spending reduction as single payer — then I would prefer the less disruptive route."

Prof. Douglas Wren (#2, R) — P1 yes, P2 yes, P3 yes, P5 no, P6 yes.
"I voted for P6 because the referees were right: CBO's 10 million is the best estimate, and I would rather the savings come from people who don't meet the requirement than from paperwork. Several colleagues on the right read the certification clause as indefinite delay. What would change my mind on P5: CBO evidence that a capped restoration costs substantially less per newly insured person than Medicaid does."

Prof. Hannah Okafor (#9, C) — P1–P3 yes, P4 no, P8 yes.
"I proposed a backstop cap and then voted against the version on the table because 200% of Medicare in every concentrated market, phased in over 5 years, is too blunt without a Maryland-style global-budget evaluation behind it. What would change my mind: a rigorous evaluation showing a state commercial price cap reduced prices without measurable declines in access or quality."

Prof. Alan Whitmore (#46, C-R) — P1 yes, P3 yes, P7 yes.
"The EPIC Act is the one change the innovation evidence can support without claiming too much. What would change my mind: if small-molecule share of Phase I starts from U.S. firms does not fall relative to 2019–2022 by 2031, I'll concede the pill penalty was overstated and support keeping the 9-year clock."

Prof. Priya Venkataraman (#19, L) — P5 yes, P7 no.
"EPIC as drafted gives up savings with nothing in return. What would change my mind: a version that brings biologics forward to offset the lost savings, or FDA novel approvals falling more than 5% below the 2018–2025 average over 2027–2031."

Stage 8: VERDICT — Prof. Adelaide Wainwright (#100, moderator)

Established

1. The U.S. spends about twice the peer average per person ($14,775 vs. $7,860 in 2024 on the OECD concept; NHE $5.3T, 18.0% of GDP, $15,474 per capita). No serious dispute.
2. **Most of the level gap is in hospital and physician care, and most of that is price, not visits or bed-days** (Papanicolas 2018; Anderson 2019; Peterson-KFF). This is the most robust finding in the domain.
3. Commercial prices are the core of the price problem, averaging 254% of Medicare for hospitals (RAND 2022 data), and provider market power, not cost-shifting, is the leading explanation (CBO 2022; Cooper et al.). The cost-shift argument should be retired from serious debate.
4. Cost sharing reduces the quantity of care, both valuable and wasteful; it has not been shown to make patients shop on price (RAND HIE; Brot-Goldberg et al.).
5. Coverage delivers large financial protection and mental-health benefits (Oregon); its short-run effect on physical-health markers is not established by the RCT.
6. CBO projects the 2025 reconciliation law will raise the uninsured by 10 million by 2034, with another ~4.2M attributable to expiration of the enhanced PTCs. Realized 2025 uninsurance was flat (7.9% Census) because the major Medicaid provisions start after 2026; marketplace enrollment has already fallen ~2.9M.
7. The U.S. life-expectancy gap (79.0 vs. 82.7) is concentrated in external causes and cardiometabolic disease, not cancer, and is disproportionately a working-age phenomenon.

Contested

• Growth vs. level: CMS attributes most 2024 per-capita growth to use and intensity. "It's the prices" explains the level, not necessarily the trajectory.
• Administrative waste: 7.6% (narrow) vs. 34.2% (broad) of spending; how much is recoverable without rate cuts is unknown.
• Single payer's net cost to the nation: CBO's range spans −$0.7T to +$0.3T in 2030, and the sign turns on payment rates and cost sharing. The federal cost is not in doubt (+$1.5–3.0T/yr per CBO; $32.6T/10 yrs per Mercatus), and the tradeoff with waits is acknowledged.
• Innovation cost of negotiation: CBO's ~1% versus much larger industry-affiliated estimates.
• Whether coverage explains part of the mortality gap: the Oregon RCT versus quasi-experimental Medicaid-expansion studies.
• NP scope-of-practice quality effects.

Unknown (needs time, not argument)

• The realized coverage effect of work requirements, which begin after Dec 31, 2026.
• Whether posted hospital prices change negotiated rates.
• Post-2026 R&D pipeline response to the IRA, especially the small-molecule share.
• Whether the 2024 overdose decline (−26%) holds and closes part of the LE gap.

Research agenda

1. Independent evaluation of state commercial price caps and all-payer models (Maryland and others) on prices, access and quality.
2. Pre-registered tracking of Phase I starts by modality from 2026 to 2031 (tests Whitmore's and Venkataraman's predictions).
3. State-level event studies on work-requirement rollout, covering coverage, employment, medical debt and mortality among 50–64-year-olds (tests Mercer's, Wren's and Reilly's predictions).
4. Causal studies of transparency data used by employer purchasers compared with consumers (tests Albrecht's prediction).
5. A reconciled administrative-cost accounting that separates insurer overhead, provider billing, and clinical documentation.

Consensus reforms (≥60% in every bloc)

P1 staged site-neutral payment · P2 dollar-price transparency enforcement routed to purchasers/enforcers · P3 competition package · P8 NP full-practice incentive + primary-care GME. All four target the price and supply side of the problem, which is where the evidence is strongest and where the blocs' diagnoses converged. None comes close to closing the peer gap by itself. Taken together they are an order of magnitude smaller than the problem, and every bloc said so.

Near-miss: P6, which would implement work requirements through automated verification, fell three Right votes short. This is the most promising bridge on coverage.

Where Symposium 1-style debate was too glib on this domain

(I have not re-audited every line of Symposium 1. These are the shallow claims this round tested and corrected.)

1. "It's all prices" holds for the level gap, but not for recent growth or for variation within the U.S.
2. "Single payer pays for itself through admin savings" is not supported. Savings, where they exist in CBO's modeling, come mainly from lower payment rates and carry a queueing tradeoff.
3. "Hospitals charge private patients more because Medicare underpays" is contradicted by CBO.
4. "HSAs will make patients shop and cut prices" is not supported by the best quasi-experimental evidence.
5. "The Medicaid changes only remove ineligible people" is contradicted by CBO's 10M projection, most of which is procedural loss.
6. "The IRA will gut innovation" and "it has no innovation cost" both outrun the evidence. CBO's ~1% is the only official estimate, and outcome data do not exist yet.
7. "Uninsurance explains our lower life expectancy" is too simple. Overdoses, injuries and cardiometabolic disease dominate the gap.

— A. Wainwright (#100)

Independent Audit

Audit Panel: Prof. Laura Pennington (#97, operations research, C) and Prof. Olivia Brandt (#57, statistics, C). Brandt also refereed this thread, so Pennington leads. Brandt recuses on any finding that concerns her own Stage 1 or Stage 4 rulings. Corrections below are additions to the record. Nothing is deleted.

1. Source check (16 claims, weighted toward the Brief, the fact-check and the Verdict)

# · Claim · Figure cited · Figure verified · Status · URL
1 · NHE 2024 · $5.3T, +7.2%, 18.0% of GDP (17.7% in 2023), $15,474 per capita · Same. Per capita is taken from the CMS fact sheet, since the Highlights PDF does not give it · Confirmed · cms.gov/files/document/highlights.pdf ; cms.gov/…/nhe-fact-sheet
2 · Growth decomposition (Brief #10) · use/intensity 3.6 pts vs. price 2.5 pts · Same, out of 6.1% per-capita growth · Confirmed · healthaffairs.org/doi/10.1377/hlthaff.2025.01683
3 · OECD comparison (Brief #4) · $14,775 vs. $7,860; about $5K more than Switzerland; 17.2% vs. 11.2% of GDP · Same · Confirmed · healthsystemtracker.org/chart-collection/health-spending-u-s-compare-countries/
4 · RAND 5.1 (Brief #13) · 254% of Medicare; 255/289/188/170; >4,000 hospitals · Same. The state range (MI/MA <200%, CA/FL/NY >300%) also matches · Confirmed · rand.org/news/press/2024/05/13.html
5 · CBO on market power and cost-shifting (Brief #14; this drives Stage 4 row 36 and Verdict item 3) · Public-payer share is "not related" to commercial prices · Exact quote present · Confirmed · cbo.gov/publication/57422
6 · Site-neutral (Brief #15) · $4B / $39B / $102B; MedPAC −3.8% OPPS; beneficiary cost-sharing "~$1.5B (2021)" · $4B/$39B/$102B and −3.8% match. We could not find $1.5B on the page. KFF says drug-administration alignment would cut cost-sharing by about $1 on average in 2021, and by $1,055 for the heaviest chemotherapy users · Minor discrepancy (the $1.5B figure) · kff.org/medicare/five-things-to-know-about-medicare-site-neutral-payment-reforms/
7 · Census 2025 (Brief #20) · 26.7M (7.9%); Medicaid −0.5 pts · Same · Confirmed · census.gov/newsroom/press-releases/2026/income-poverty-health-insurance-coverage.html
8 · CBO on OBBBA (Brief #22) · +10M uninsured in 2034; $1.06T; $325.6B / $191.1B / $149.4B; deficit +$3.4T · Same · Confirmed · aha.org/news/headline/2025-07-21-cbo-projects-obbba-…
9 · Marketplace 2026 (Brief #25) · 22.1M → 19.2M; net premiums +58%; +114% to keep the same plan; deductibles +37%; 17.5M projected · Same · Confirmed · kff.org/quick-insights/aca-marketplace-enrollment-is-down-by-3-million-…
10 · IRA negotiation (Brief #26) · R1 $6B, 22% net, $1.5B OOP; R2 $12B, ~44% net; 40 drugs = 36% of Part B+D spending; semaglutide $274 vs. $959 · All match. BioPharma Dive calls the 44% "over 2024 list prices" and KFF calls it net, so the Takahashi referee note is accurate · Confirmed · kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/ ; biopharmadive.com/…/806526/
11 · CBO innovation effect (Brief #27) · 13 of 1,300 drugs over 30 years; $98.5B · Same · Confirmed · kff.org/medicare/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
12 · Overdoses (Brief #32) · 79,384 deaths; 31.3 → 23.1 (−26.2%); synthetic opioids −35.6% · Same · Confirmed · cdc.gov/nchs/products/databriefs/db549.htm
13 · Life-expectancy gap (Brief #30) · 79.0 vs. 82.7 · Same · Confirmed · healthsystemtracker.org/chart-collection/u-s-life-expectancy-compare-countries/
14 · PRA compliance (Brief #16) · 49.4% (8th review, 2,000 hospitals), up from 21% · Same · Confirmed · patientrightsadvocate.org
15 · Mercatus (Brief #36; Stage 4 row 9) · $32.6T; 10.7% of GDP (2022) rising to 12.7% (2031); payments >40% below private rates · Same · Confirmed · mercatus.org/…/costs-national-single-payer-healthcare-system
16 · Arkansas 2018 work requirement (row 42) · about 18,000 lost coverage; no employment gain · Not checked. NEJM returned 403, PubMed returned a CAPTCHA, and the KFF page returned 404 · Could not access · —

Counts: Confirmed 14 · Minor discrepancy 1 · Not supported 0 · Could not access 1.

2. Internal consistency

• Vote math: we recomputed all 24 percentages. Every one is correct. The consensus labels are correct: P1, P2, P3 and P8 pass. P6 is 17 out of 32 on the Right, which is 3 short, as stated. The notes also check out: 10 Left no votes on P1 (34 − 24) and 11 Right no votes on P3 (32 − 21).
• Fact-check tally: 48 rows. We count S 31, C 6, U 5, W 6, which matches the tally line.
• Roster: every name, number, field and lean matches the Symposium 1 roster.
• Correction A (P5 precedent): the enrollment figures "16.2M (2023) → 21.1M (2024)" are cited to "[2]". Brief item 2 is per-capita NHE, so the citation is wrong, and these two figures appear nowhere in the Brief. Treat them as unsourced in this thread. The 22.1M → 19.2M figures remain sourced to Brief #25.
• Correction B (Brief #15): the "$1.5B" MedPAC beneficiary cost-sharing figure should be treated as unverified (see row 6). It does not affect any rating or vote.
• Correction C (cross-examination X5 vs. X11): in X5, Whitmore says round 1's 22% is net. In X11 he is then rebutted for claiming it was off list, and he retracts. The record is internally inconsistent. The Stage 4 "Wrong" rating (row 31) still stands, because it applies to his Stage 2 opening. Also worth noting: trade press (BioPharma Dive) itself frames round 2 as "44% over list," so the confusion has an outside source.
• Correction D (Verdict, "too glib" item 5): the Verdict says CBO's 10M is "most of which is procedural loss." That is Wren's characterization from X10, and no source in the Brief backs it. CBO does not break the 10M into procedural and substantive losses anywhere in the Brief. It should read "a projection that, per the panel's discussion, is likely driven substantially by procedural disenrollment (not quantified in this record)."
• Verdict items 1 through 7 do not reuse any claim that was rated Wrong or Unsupported. The "Established" list is consistent with Stage 4.

3. Balance

Six claims were rated Wrong: 1 Left (Mercer), 2 Center (Chen, Albrecht) and 3 Right (Wren, Whitmore, Pruitt). Every Wrong rating rests on a primary source we confirmed above, including CBO 57422, KFF on the IRA and CBO/AHA on OBBBA. The one call we consider slightly harsh is row 27 (Wren, "coverage loss will be small"). It is a forecast judged against another forecast, CBO's projection. The parallel Left overreach, Mercer's claim that the life-expectancy gap is "fundamentally" about coverage (row 5), was rated Unsupported rather than Wrong. For symmetry, row 27 would be better rated Unsupported or Contested against CBO. That change would not alter any vote or any Verdict finding. Overall, the Verdict follows the evidence, and the consensus list (supply and price side) matches where the blocs actually converged.

4. Grade: A−

Nearly every consequential number checks out against its primary source, and the vote and tally arithmetic is exact. The grade is held back by one miscited precedent (P5), one unsourced phrase in the Verdict, and one slightly asymmetric Wrong rating.

— Pennington (lead); Brandt recused on Stage 1/4 rulings

Verdict v2 (audit-corrected)

Prof. Adelaide Wainwright (#100, moderator). I am appending this post to the record and leaving every earlier post as it was. It resolves the claims the thread left unverified and the items the audit flagged. It moves the Stage 4 tally onto the standard scale: Supported, Contested, Unsupported (which includes "could not verify") and Wrong. It then restates the verdict with the corrected figures. All sources were fetched on 2026-09-24.

1. Resolution of unverified and audit-flagged items

Item · Claim · Result · Figure and source
Row 42 (audit: could not access) · Arkansas 2018: ~18,000 lost coverage, no employment gain · Now verified · "18,000 adults leaving Medicaid in late 2018." There was no change in employment. Over 95% of the target population already met the requirement or qualified for an exemption. A third had not heard of the requirement. From Sommers et al., NEJM 2019, via Harvard Chan School. The primary paper is NEJM, which returned 403 to the audit
Row 47 · Negotiated-price discounts of "38–79%" off list · Now verified · CMS: "These negotiated prices range from 38 to 79 percent discounts off of list prices" (round 1). The same release gives $6B (≈22%) Medicare savings and $1.5B out-of-pocket savings. CMS, 2024-08-15
Brief 15 (audit: minor discrepancy) · MedPAC beneficiary cost-sharing "~$1.5B (2021)" · Now verified · Across all 66 APCs, alignment "would have reduced Medicare OPPS outlays… in 2021 by $6.0 billion and beneficiary cost sharing by $1.5 billion" (for 57 APCs: $4.9B and $1.2B). MedPAC June 2023, ch. 8. Note: MedPAC puts the reduction at 3.2% of OPPS hospitals' total Medicare revenue. The thread's "3.8% of OPPS revenue" (via KFF) may use a different denominator. We have not reconciled the two
P5 precedent (audit: unsourced) · Marketplace enrollment 16.2M (2023) → 21.1M (2024) · Corrected · The CMS full-year average effectuated enrollment was 16.2M (2023) → 21.0M (2024), up 30%. February snapshots were 15.7M (2023), 20.8M (2024) and 23.4M (2025). CMS 2024 report; CMS 2025 report. The "22.1M (2025) → 19.2M (2026)" pair comes from a different (KFF) series and should not be chained onto the CMS averages
Verdict glib item 5 (audit) · CBO's 10M, "most of which is procedural loss" · Still unverifiable as a CBO finding; partly supported by precedent · CBO does not split the 10M into procedural and substantive losses. The Arkansas precedent (>95% already compliant or exempt, yet ~18,000 lost coverage) shows that the losses there were mainly failures to report or document. The text is corrected below
Row 11 · NPs deliver equal quality at lower cost · Still unverifiable · No study was fetched within budget
Row 24 · Consumer-facing transparency doesn't lower prices · Still unverifiable · The claim asserts that no effect exists. No causal study was fetched
Row 26 · Restored eAPTCs mostly subsidize the already-insured · Still unverifiable · No cost-per-newly-insured source was found
Row 39 · U.S. spending largely reflects high income · Still unverifiable · Unsourced. The speaker conceded the U.S. is above trend
Brief 28 · Philipson "pill penalty" headline count · Still unverifiable · As flagged in the Brief
P3 precedent · State bans on anti-tiering/anti-steering clauses · Still unverifiable · Not checked
P4 precedent · Maryland all-payer model · Still unverifiable · Not checked in this pass
P1 precedent · Site-neutral implemented without access collapse · Still unverifiable · No outcome evaluation was fetched

2. Rating normalization

This thread defined C to include "plausible but unsourced in this thread." On the standard scale, those claims are U. I have reclassified four rows from C to U: 11, 24, 26, 39. Rows 29 and 32 stay C because the evidence on them is genuinely split. I also adopt the audit's symmetry correction: row 27 (Wren, "coverage loss will be small") was a forecast judged against CBO's forecast, so it moves from W to U, to match how Mercer's row 5 was rated.

· Supported · Contested · Unsupported · Wrong
Stage 4 as published · 31 · 6 · 5 · 6
Normalized (C→U ×4; row 27 W→U) · 31 · 2 · 10 · 5
After resolutions (rows 42, 47 → S) · 33 · 2 · 8 · 5

Old → new: S31 · C6 · U5 · W6 → S33 · C2 · U8 · W5 (48 claims). Whitmore and Mercer had withdrawn rows 47 and 42 pending sources. Both claims now stand as sourced.

3. Corrected verdict

Established

1. The U.S. spends about twice the peer average per person: $14,775 vs $7,860 in 2024. National health expenditure was $5.3T, 18.0% of GDP, $15,474 per capita.
2. **Most of the level gap is in hospital and physician prices.**
3. Commercial prices are the core of the price problem (254% of Medicare). Provider market power, not cost-shifting, is the leading explanation (CBO 57422; Cooper et al.).
4. Cost sharing reduces the quantity of care but has not been shown to induce price shopping (RAND HIE; Brot-Goldberg).
5. Coverage delivers large financial-protection and mental-health benefits (Oregon). Its short-run effect on physical markers is not established.
6. CBO projects +10M uninsured by 2034 from the 2025 law, plus ~4.2M from eAPTC expiration. Uninsurance in 2025 was flat (7.9%). Corrected: marketplace enrollment rose from a 16.2M (2023) to 21.0M (2024) full-year average under eAPTCs (CMS). The post-expiration decline (22.1M → 19.2M) is a separate KFF series.
7. The LE gap (79.0 vs 82.7) is concentrated in external causes and cardiometabolic disease.
8. (New) Reporting-based work requirements cut coverage without raising employment in the one full precedent. Arkansas 2018: ~18,000 lost coverage, no employment change, and >95% of targets were already compliant or exempt (Sommers et al., NEJM 2019).
9. (New) Round-1 negotiated prices are 38–79% below list, which works out to ~22% below net in aggregate (CMS). Both framings are correct. They measure against different baselines.

Contested

• Growth vs level (use and intensity drove most 2024 per-capita growth).
• Administrative waste: 7.6% (narrow definition) vs 34.2% (broad).
• Single payer's net national cost (CBO −$0.7T to +$0.3T in 2030).
• The innovation cost of negotiation (CBO ~1% vs industry-affiliated estimates).
• Whether coverage explains part of the mortality gap (Oregon vs quasi-experimental studies).

Unknown

• The realized coverage effect of the 2025 law's work requirements, which begin after 2026.
• Whether posted hospital prices change negotiated rates.
• The post-2026 R&D response to the IRA.
• Whether the 2024 overdose decline (−26%) holds.
• NP scope-of-practice quality effects. Moved from Contested to Unknown, because no study was verified in-thread. This is a gap in the evidence, not a split in it.
• (Added) Cost per newly insured person under restored eAPTCs.

Glib-claims item 5, corrected: "The Medicaid changes only remove ineligible people" is contradicted by CBO's 10M projection. The Arkansas precedent suggests much of that loss could come from people who meet the requirement but fail to report it (Arkansas: >95% of the target population was compliant or exempt). CBO does not quantify this split, and "most of which is procedural" should not be read as a CBO finding.

Conclusions that changed.
(a) P6 (automated verification) now has a verified evidentiary basis. The Arkansas outcome it is designed to prevent is sourced: coverage losses with no employment gain among a population almost entirely compliant or exempt. This strengthens the case for P6 on the evidence. It does not settle the values dispute over budget savings.
(b) P5's precedent figures are corrected: 21.0M, not 21.1M, and from a different series than the 2025–26 numbers.
(c) NP quality moves from Contested to Unknown.
(d) Row 27 moves from W to U. No verdict finding depended on it.
(e) The MedPAC $1.5B figure stands. The OPPS revenue share should be quoted as 3.2% of hospitals' total Medicare revenue (MedPAC) unless the KFF 3.8% denominator is specified.

I have left the consensus list as recorded.

— A. Wainwright (#100)